Cargando…

Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials

Several randomized clinical trials have suggested the effectiveness of bevacizumab (Bev) in early and advanced breast cancer; however, due to the increased toxicity and lack of a clear long-term survival benefit, there is currently no defined role for Bev in breast cancer in the USA, while it has be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nahleh, Zeina, Botrus, Gehan, Dwivedi, Alok, Jennings, Michael, Nagy, Shaimaa, Tfayli, Arafat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388502/ https://www.ncbi.nlm.nih.gov/pubmed/30847174 http://dx.doi.org/10.3892/mco.2019.1796

Ejemplares similares

Disparities in Metabolic Conditions and Cancer Characteristics among Hispanic Women with Breast Cancer: A Multi-Institutional Study
por: Jabbal, Iktej S., et al.
Publicado: (2022)

Disparities in breast cancer: a multi‐institutional comparative analysis focusing on American Hispanics
por: Nahleh, Zeina, et al.
Publicado: (2018)

Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy
por: Elzamly, Shaimaa, et al.
Publicado: (2018)

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region
por: Tfayli, Arafat Hussein, et al.
Publicado: (2019)

Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer
por: Philipovskiy, Alexander, et al.
Publicado: (2020)

Complementary and alternative medicine use and its association with quality of life among Lebanese breast cancer patients: a cross-sectional study
por: Naja, Farah, et al.
Publicado: (2015)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Non-Autoimmune Hemolytic Anemia with Clostridium Ramosum Bacteremia
por: Al-kali, Aref, et al.
Publicado: (2008)

Long-Term Effect of a Nonrandomized Psychosocial Mindfulness-Based Intervention in Hispanic/Latina Breast Cancer Survivors
por: Elimimian, Elizabeth, et al.
Publicado: (2020)

Comparative Outcome of Computed Tomography-guided Percutaneous Radiofrequency Ablation, Partial Nephrectomy or Radical Nephrectomy in the Treatment of Stage T1 Renal Cell Carcinoma
por: Cooper, Chad J., et al.
Publicado: (2015)

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
por: Jiang, Wei, et al.
Publicado: (2018)

Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report
por: Fakhri, Ghina, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
por: Mina, Alain, et al.
Publicado: (2015)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
por: Li, Cunfu, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
por: Changavi, Arathi A, et al.
Publicado: (2015)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis
por: Chen, Xiao-song, et al.
Publicado: (2014)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis
por: Zhang, Shichao, et al.
Publicado: (2023)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
por: Kim, Aeri, et al.
Publicado: (2017)

Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
por: Cho, Dong Hui, et al.
Publicado: (2013)

Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report
por: Yu, Jing, et al.
Publicado: (2022)

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
por: Jerusalem, Guy, et al.
Publicado: (2023)

Rhodococcus equi venous catheter infection: a case report and review of the literature
por: Guerrero, Rosalinda, et al.
Publicado: (2011)

Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US
por: Elimimian, Elizabeth B., et al.
Publicado: (2021)

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation
por: Saade, Lili Jose, et al.
Publicado: (2023)

Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2
por: Arumugam, Arunkumar, et al.
Publicado: (2019)

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis
por: Ma, Xuelei, et al.
Publicado: (2016)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy
por: Wang, Liye, et al.
Publicado: (2021)

Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
por: Zugman, Miguel, et al.
Publicado: (2022)

The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Richter, Igor, et al.
Publicado: (2015)

Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
por: Meng, Xiangjiao, et al.
Publicado: (2014)

How to reduce your cancer risk: mechanisms and myths
por: Nahleh, Zeina, et al.
Publicado: (2011)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3v0tevd2d2dq2026nioo406uml